Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Drug:
NY-ESO-1 peptide vaccine
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II Study of ESO-1 Peptide Vaccine in HLA-A*201 or HLA-DPB1*04 Positive Patients With Refractory Metastatic Melanoma Expressing ESO-1
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-01-C-0032
, NCI-2390, 2390, NCT00020397
2.
Phase II Study of Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, ESO-1 Peptide Vaccination Comprising ESO-1:157-165 (165V) Peptide and Montanide ISA-51, and Interleukin-2 in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-04-C-0104
, NCI-6233, 6233, NCT00079144
3.
Study of NY-ESO-1 ISCOMATRIX® in Patients With High-Risk, Resected Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
LUD2003-009
, NCT00199901
4.
Phase I Pilot Study of NY-ESO-1 Peptide Vaccine and Sargramostim (GM-CSF) in Patients With Stage II, III, or IV Soft Tissue Sarcoma Expressing NY-ESO-1 or LAGE Antigen
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CPMC-IRB-13578
, LUDWIG-LUD00-024, NCI-G01-2035, NCT00027911
5.
Phase I Pilot Randomized Study of Melanoma Peptide Vaccine With or Without Sargramostim (GM-CSF) in Patients With High-Risk or Metastatic Melanoma
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CPMC-IRB-13824
, LUDWIG-LUD00-025, NCI-G02-2068, NCT00037037
6.
Phase I Study of NY-ESO-1b Peptide Vaccine and Montanide ISA-51 in Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Expressing NY-ESO-1 or LAGE-1
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-03034
, LUDWIG-LUD2002-014, NCT00066729
7.
Phase I Pilot Study of NY-ESO-1 Peptide Vaccine, BCG, and Sargramostim (GM-CSF) in Post-Cystectomy Patients With Transitional Cell Carcinoma of the Bladder Expressing NY-ESO-1 or LAGE-1 Antigen
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-03047
, LUDWIG-LUD2002-004, NCT00070070
8.
Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
LUD2002-005
, NCT00106158
9.
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
NYU 04-53, LUD2004-006
, NCT00142454
10.
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
LUD2003-022;NYU05-120;CUMC9147
, NCT00299728
11.
Pilot Study of Adjuvant Vaccine Therapy Comprising HLA-DP4-Restricted NY-ESO-1 p157-170 Peptide and Montanide ISA-51 in Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer That Expresses NY-ESO-1 or LAGE-1
Phase:
No phase specified
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RPCI-RP-0228
, LUDWIG-LUD-02-011
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute